Project summary: The goal of this study is to establish the feasibility of My Guide in delivering a remote, adaptive, intervention to improve adherence to endocrine therapies (ET), health-related quality of life (HRQoL) and ET side effects among Hispanic breast cancer survivors (N= 60). We hypothesize our intervention will meet established markers of feasibility and that participants will report improved breast cancer knowledge, self-efficacy, reduced ET side effects, and improved HRQoL. We also hypothesize adherence will either remain stable or improve throughout the 3-month trial but will not decline. These pilot data will be essential to establishing the feasibility of a remote, web-based oral medication adherence trial as well establish our ability to recruit and retain an underserved and hard-to-reach patient population such English and/or Spanish-speaking Hispanic breast cancer survivors. This pilot project will establish the feasibility of our multi-site protocol and provide the necessary pilot data to inform the development of a larger multi-site (4-5 recruitment site) ECOG-ACRIN protocol to assess the efficacy of our intervention. Recruitment will take place at Northwestern University and Montefiore Medical Center with each site recruiting approximately 30 participants between 9/14/2020-7/31/2021. Montefiore will identify potentially eligible patients . With patient approval, these patients will be referred to the study coordinator at Northwestern for study screening and consenting. Research staff across both sites will meet on a weekly basis to discuss progress on recruitment and participant engagement in the trial.
|Effective start/end date||9/1/20 → 7/31/22|
- ECOG-ACRIN Medical Research Foundation, Inc. (UG1CA189828-07-NWU4//5UG1CA189828-07)
- National Cancer Institute (UG1CA189828-07-NWU4//5UG1CA189828-07)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.